The next cash cow in the medical equipment industry - artificial heart
It may be too early to make a prediction, but the whole artificial heart may be the next cash cow in the medical technology field; Carmat, an artificial heart manufacturer from France, was recently rumored that the company’s technology has been successfully implanted in the second. In the body of patients, the stock price has risen by nearly 20%. If the artificial heart is finally suitable for most patients, as a long-term treatment solution for heart disease, artificial heart players such as Carmat will be able to explore a larger market. .
According to statistics, in the United States, about 600,000 people die of heart disease every year. Heart transplantation can be said to be in short supply, and transplanting the heart can only solve a small number of patients with chronic heart failure. A report by the technology blog Motherboard reporter Zoltan Istvan predicts that the entire artificial heart will be widely used within a decade; but for the medical device industry that needs to overcome various obstacles, this breakthrough technology may not be too fast.
The cardiovascular drug delivery stent (drugelutingstent), considered to be the last heavyweight weapon in the medical industry, is on the market; not long ago, Kidney sympathectomy, considered to be the next major potential treatment for heart disease, is now possible Will be judged "to the pre-hospital death (DOA)" - perhaps this statement is exaggerated, but because the medical device manufacturer Medtronic's SymplicityKidney sympathetic nerve removal system failed to pass a key clinical trial, the industry expects that The development of technology will be severely limited.
At the same time, the number of cases of artificial heart transplants is increasing. According to Istvan, over 1,000 artificial hearts have been used in the past 35 years – but usually short-term; in addition, more than 11,000 left ventricular assists Left-ventricular associative devices (LVAD) are implanted in patients. In 2010, former US Vice President Dick Cheny completed a heart transplant with LVDS as a transitional technology; although LVDS was initially considered a transitional technology, it has now progressed to permanent treatment for some patients with heart disease. the way.
Food Additives Powder,Sophora Extract,Propoli Liquid Extract,Apple Cider Vinegar Powder
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com